[68Ga]Ga-DOTA-TOC or Ga-68 DOTATOC is a radiopharmaceutical that has gained regulatory approval for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors (NET) when positron emission tomography (PET) is used. It is a combination of radionuclide 68Ga and the somatostatin analogue DOTA-TOC. Industry investments in the Ga-68 DOTATOC market have risen on the back of the use of Ga-68 DOTATOC in the localization of SSTR-positive NETs. The molecule has been utilized in PET for staging and restaging of NET and is useful in the management of NET. They are suitable for both adult and pediatric patients. It is administered as an intravenous injection.
The growing adoption of PET in identifying and evaluating the extent of NET is a direct driver for the growth in the Ga-68 DOTATOC market. Further, they are helpful in the evaluation of treatment response. The demand for PET tracers has gained traction in nuclear medicine, and helps in managing prevalence of neuroendocrine tumors. They prominently assist biomarker findings.
The global Ga-68 DOTATOC market is evolving on the back of increasing incidence of NET, since the improvement in diagnosis rate is a result of imaging modalities. In the U.S. alone, more than 12,000 people are diagnosed with NET. A number of clinical trials including comparison studies have evaluated the sensitivity and specificity of radiopharmaceutical. Increased awareness of NETs along with the strides in nuclear medicine are expanding the outlook of the Ga-68 DOTATOC market.
The rise in adoption of a remarkable imaging agent is a key aspect propelling the product approval of Ga-68 DOTATOC in various countries. Worldwide, over the past few years, theranostic approach has gathered steam in health care, particularly personalized (precision) nuclear medicine, fueling the uptake of Ga-68 DOTATOC in the PET scan. The emergence of new PET tracers is a key trend in the diagnosis of NETs.
The market has also received a significant and steady momentum from pharmacology and pharmacokinetics of somatostatin analogs.
In 2019, Ga-68 DOTATOC has been approved by the Food and Drug Administration (FDA) for NET in the U.S. The molecule has already been approved for Austria, Germany, and France. These all paint a promising picture of the future prospects in the Ga-68 DOTATOC market. Stakeholders including industry players are reaping revenue gains from the need for advancing therapy planning in NETs. The market players are keen on expanding the evaluation of treatment response. Small facilities are engaged more in the decentralized preparation of Ga-68 DOTATOC. Key players have also benefited from metaanalysis of the indications that 68Ga-DOTATOC can be used.
However, genuine impediments to the avenue are high costs of diagnostic equipment and lack of physician who can handle radiopharmaceutical. Pancreatic neuroendocrine tumors are a promising segment in the Ga-68 DOTATOC market.
Numerous players are adopting strategic collaboration, acquisitions and mergers to consolidate their shares in the market. Some of the key industry stakeholders in the Ga-68 DOTATOC market are Seimens AG, Synergy Pharmaceuticals, Amgen Inc. Biosynthema, Mayroy SA, Bristol Myers Squibb Company, Eli Lilly & Company, Roche Holding AG, and Pfizer Inc.
The global Ga-68 DOTATOC market is expected to see massive revenue potential in North America and Europe. The marked incidence of NETs in the regional populations has propelled the demand. Furthermore, advancements in Diagnostic technologies used in NET and extensive clinical studies on the nuclear medicine are opening new paths of development in the regional market.
Increasing awareness about the NETs in Asia is one of the key growth drivers for new avenues in the Ga-68 DOTATOC market.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure (PDF) sent to your email within minutes
Complete the form below and we'll get back to you shortly.